Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale

Parkinsonism Relat Disord. 2019 Jan:58:79-82. doi: 10.1016/j.parkreldis.2018.08.018. Epub 2018 Aug 26.


Background: Motor complications represent an important clinical problem in the treatment of Parkinson's disease (PD). The Motor Complications Part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part IV) and the Unified Dyskinesia Rating Scale (UDysRS) are among the most reliable instruments to evaluate these problems. The minimal clinically important difference thresholds are the smallest changes in the outcome measures that are clinically meaningful.

Aims: The aim of our study was to calculate the minimal clinically important difference thresholds for the MDS-UPDRS Part IV and the historic parts of the UDysRS.

Methods: A total of 1044 paired investigations of 436 patients were analyzed. Changes in the respective outcome measures (MDS-UPDRS Part IV, UDysRS Parts I and II) were compared to the Patient-rated Global Impression of Improvement scores (anchors). Subsequently, we applied receiver-operating characteristic analysis to ascertain the MCID thresholds with optimal sensitivity and specificity.

Results: Any improvement greater than 2.1 points or any worsening greater than 1.8 points on UDysRS Part I represents a minimal, yet clinically meaningful change. In reference to UDysRS Part II, the smallest changes considered clinically relevant are 1.8 and 1.7 points for improvement and deterioration, respectively. The thresholds for the MDS-UPDRS Part IV are 0.9 points for improvement and 0.8 points for worsening.

Conclusions: Our estimates may allow the judgment of the clinical relevance of numeric changes in the dyskinesia scales.

Keywords: Minimal but clinically relevant differences; Minimal clinically important changes; Parkinson disease; Receiver operating characteristic curve; Unified Dyskinesia Rating Scale.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / pharmacology
  • Dyskinesias / diagnosis*
  • Dyskinesias / drug therapy
  • Humans
  • Minimal Clinically Important Difference*
  • Movement Disorders / diagnosis*
  • Movement Disorders / drug therapy
  • Outcome Assessment, Health Care / standards*
  • Parkinson Disease / diagnosis
  • Parkinson Disease / drug therapy
  • Severity of Illness Index*


  • Antiparkinson Agents